G2 Capital Management’s AbbVie ABBV Stock Holding History

G2 Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,001	Closed	-$870K	–	71
2026 Q1	$870K	Buy	+4,001	New	+$888K	0.21%	36
2022 Q1	–	Sell	-4,026	Closed	-$545K	–	50
2021 Q4	$545K	Buy	+4,026	New	+$476K	0.2%	41

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

G2 Capital Management's ABBV Position: Q2 2026 in Review

G2 Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 4,001 shares — an estimated $870K sold.

G2 Capital Management first reported a position in ABBV in Q4 2021 and held it in 2 quarters. The position peaked at $870K in Q1 2026. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

G2 Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
G2 Capital Management sold 4,001 AbbVie shares in Q2 2026, an estimated $870K.
G2 Capital Management first reported a position in AbbVie in Q4 2021 and held it in 2 quarters.
G2 Capital Management's AbbVie position peaked at $870K in Q1 2026.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on G2 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.